Trial Profile
Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 rhIGF-1) Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency: A Six-year, Randomized, Multi-center, Open-label, Parallel-group, Active Treatment Controlled, Dose Selection Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary) ; Somatropin (Primary)
- Indications Short stature
- Focus Therapeutic Use
- Sponsors Ipsen
- 14 Dec 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 12 May 2014 New trial record